Janone inc. announces an improved formulation of jan101

Recent developments at the university of iowa have resulted in an improved formulation of jan101 las vegas , june 28, 2022 /prnewswire/ -- janone inc. ("janone") (nasdaq: jan), a company that focuses on the development of drugs with non-addictive, pain-relieving properties, announced today that work has been completed by dr. maureen donovan at the university of iowa that will allow for an improved formulation of jan101. jan101 (formerly known as tv1001sr), is a potential treatment for peripheral artery disease (pad), a vascular disease that affects more than 8.5 million people in the u.s. and more than 60 million people worldwide.
JAN Ratings Summary
JAN Quant Ranking